“Then, by the beginning of 2021, we expect a few million doses,” Fawcett said during a direct question and answer session with the Journal of the American Medical Association.
However, it is not yet clear whether the vaccine will be effective against the coronavirus novel.
Fawcett said the first vaccine candidate created by the biotech company Moderna, in partnership with NIAID, would have to go through the final stages of volunteering in mid-summer, known as Phase 3. He said preparations are already underway at national and international sites.
“Hopefully this will be the end of all the real business, episode 3 starting in the first week of July” “We want to get as many datapoints as possible.”
The third phase will involve about 30,000 people. The vaccine will be tested on people aged 18 to 55, as well as the elderly and those with underlying health conditions.
“It’s going to be the whole spectrum,” Fawcett said.
Fausi said work on the second phase of the trial had begun a few days ago. Hundreds of volunteers will be part of the test.
Fawcett said there were plans to make a dose of the vaccine before it was clear whether the vaccine would be effective, Fawcett said. If it works, it can be deployed quickly.
Scientists need to have enough information by November or December to determine if the vaccine works, Fawcett said.
Tests for the AstraZeneca vaccine at Oxford University and the UK will follow a similar schedule. He added that a handful of other vaccine studies should begin one to two months later, he said.
“I’m cautiously optimistic that we have different platforms with multiple candidates, we’re taking a vaccine to make it work,” Fawcett said. He is optimistic, he said, because while the death toll from Covid-19 is “deep”, people are largely free of the disease. Recovery shows that there is an immunity that can clear the virus.
“Which tells us that if the body is able to build resistance to clear the virus of natural infections, it’s a very good proof of the concept,” Fawcett said. “There is no guarantee even after saying this.”
In fact, despite 10 vaccines already being developed in clinical trials and more than 120 more being developed, many experts doubt that a vaccine will be available early next year. The original testing stages may be delayed and, in the end, the vaccines tested now may not protect against the virus. Millions of vaccine doses produced prematurely can be discarded.
Fawcett noted that he was also concerned about the sustainability of the immune response. People develop antibodies to fight common colds caused by other strains of coronavirus, but this protection usually lasts about a year. This could mean that people will need a new vaccine every year, as is the case with influenza.
Fawcett said there was a “big push” in the program to develop exclusive antibodies, convoluted plasma and hyperimmune globulin. These are all treatments that employ antibodies such as vaccines but provide direct, provide more temporary protection and can potentially treat the symptoms of Covid-19.
Fawcett said he wanted to see advanced treatment using monochromatic antibodies or convulsant plasma that would protect the elderly and those at risk of the worst symptoms of Covid-19.
“It’s a very, very high priority,” Fawcett said.